Oncotelic Therapeutics Inc. OTLC Archives - Page 3 of 5

MondayMar 23, 2026 9:40 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego, highlighting findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics. The presentation underscores the importance of tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations. To view the full press release, visit https://ibn.fm/kZzE3 About Sapu Nano Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical…

MondayFeb 23, 2026 9:40 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” highlighting growing investor interest in clinical-stage platforms supported by existing human data. The editorial notes that programs demonstrating clinical activity offer clearer valuation benchmarks and reduced uncertainty compared with preclinical assets, positioning companies with diversified clinical pipelines, including oncology and CNS-focused targets such as TGF-β signaling and delivery-based approaches, to align with industry demand for validated mechanisms and strategic portfolio depth. To view the full press release, visit https://ibn.fm/cZmVn About Oncotelic Therapeutics Inc. Oncotelic Therapeutics…

FridayFeb 20, 2026 10:40 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS and Oncology Momentum

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the InvestorBrandNetwork. The article, titled “Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development,” highlights growing pharmaceutical interest in clinical-stage assets supported by human data and features Oncotelic as an example of a diversified clinical-stage company. The editorial notes the company’s recently expanded international intellectual property coverage for OT-101, its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology and CNS drug-delivery technologies designed to cross the blood–brain barrier. To view the full press release, visit https://ibn.fm/2SuJ3…

WednesdayFeb 18, 2026 9:30 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN (InvestorBrandNetwork), highlighting the growing focus in biotech mergers and acquisitions on de-risked, late-stage assets with clinical validation. The article, titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” examines how pharmaceutical companies and investors are prioritizing programs with established safety and efficacy data, placing companies such as Oncotelic, with multiple clinical- and late-stage oncology and central nervous system programs, in alignment with current M&A trends as it advances its…

WednesdayJan 21, 2026 1:36 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology

Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. “Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (‘SABCS’), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use,” reads a recent article. “The platform shows high-level compatibility across different therapeutic categories. All five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor(R)), and umirolimus, formed stable,…

FridayJan 09, 2026 12:20 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Advances Nanoparticle Drug Delivery, Prepares First-in-Human Study of IV Everolimus

Oncotelic Therapeutics (OTCQB: OTLC) is positioned at the heart of the evolving landscape of pharmaceutical innovation, applying ultra-small carrier technologies to elevate existing cancer therapies. “The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds,” reads a recent article. “The advantages of nanoparticle delivery in pharma are significant… The contemporary view holds that nanocarrier-enabled formulations may be as transformative for drug delivery as the advent of monoclonal antibodies was for biologics… Into this context, Oncotelic Therapeutics, which in its most recent news has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its…

TuesdayDec 23, 2025 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Unveils Breakthrough Nanomedicine Platform, Expands Everolimus (Afinitor(R)) Pipeline

OTLC’s Deciparticle(TM) platform reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, IV-ready nanoparticles. Current Preclinical PK data show that Sapu003, the intravenous Deciparticle(TM) formulation of Everolimus (Afinitor(R)), cuts down gastrointestinal drug accumulation by up to 67-fold compared to oral dosing. These advancements highlight a quickly expanding immunology and oncology pipeline built on modular, cGMP-ready nanomedicine engineering. Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging as a key player in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new…

WednesdayDec 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology

Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its Deciparticle platform Oncotelic is leveraging the very concepts of nanoparticle-mediated delivery in a real-world clinical context In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.…

MondayDec 15, 2025 11:20 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences

Oncotelic Therapeutics (OTCQB: OTLC), in collaboration with the Brush and Key Foundation, announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences titled “Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter,” which analyzes the prognostic significance of biomarkers DNMT3A and GMPS across hepatocellular carcinoma and pancreatic ductal adenocarcinoma. Drawing on survival, transcriptomic, and tumor microenvironment data from more than 7,000 patients, the study demonstrates that biomarker relevance is highly context-dependent, shaped by immune composition, metabolic reprogramming, and innate immune signaling pathways, while also highlighting the role of structured mentorship in advancing translational oncology…

MondayDec 15, 2025 9:45 am

Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics

Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”) are shifting the odds through rational design. Six new antisense drugs gained FDA approval in 2023–2024, bringing total approvals above 20; evidence of accelerating regulatory momentum. Oncotelic Therapeutics’ OT-101 (Trabedersen) is the only TGF-β2-specific antisense in Phase 3 trials, targeting pancreatic cancer and other resistant malignancies. The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates…

Site Search

Company Search

Tag: Oncotelic Therapeutics Inc. OTLC